|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.29 USD | +1.79% |
|
-3.97% | +28.50% |
| Feb. 25 | Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… |  |
| Feb. 24 | Vaxcyte, Inc., Q4 2025 Earnings Call, Feb 24, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 8.53B | - | - | - | - | - |
| 44.16B | |||||
| 40.5B | |||||
| 30.21B | - | ||||
| 25.47B | - | ||||
| 19.22B |
- Stock Market
- Equities
- PCVX Stock
- Charts Vaxcyte, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
